Lexaria Bioscience (LEXX) Common Equity (2010 - 2026)
Lexaria Bioscience (LEXX) posted Common Equity of $4.7 million for Q2 2026, down 23.7% sequentially from $6.2 million in Q1 2026, and down 8.29% YoY from $5.2 million in Q2 2025.
Lexaria Bioscience (LEXX) Common Equity (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Common Equity for 17 years, with the latest figure at $4.7 million in Q2 2026.
- Quarterly Common Equity fell 8.29% year-over-year to $4.7 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.7 million (down 8.29% YoY) and the FY2025 annual result came in at $2.6 million, down 66.02% from the prior year.
- Common Equity eased to $4.7 million in Q2 2026 per LEXX's latest filing, from $6.2 million in the prior quarter.
- Over five years, Common Equity peaked at $11.2 million in Q1 2022 and troughed at $2.6 million in Q3 2025.
- A 5-year average of $6.2 million and a median of $6.0 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity jumped 185.78% in 2024, then slumped 66.02% in 2025.
- Over 5 years, Common Equity stood at $5.9 million in 2022, then plunged by 43.14% to $3.4 million in 2023, then soared by 178.53% to $9.4 million in 2024, then slumped by 51.85% to $4.5 million in 2025, then rose by 4.75% to $4.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $4.7 million, $6.2 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.79 Bn |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | 4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 4.74 Mn |
| Feb 28, 2026 | 6.21 Mn |
| Nov 30, 2025 | 4.52 Mn |
| Aug 31, 2025 | 2.60 Mn |
| May 31, 2025 | 5.17 Mn |
| Feb 28, 2025 | 6.76 Mn |
| Nov 30, 2024 | 9.39 Mn |
| Aug 31, 2024 | 7.66 Mn |
| May 31, 2024 | 9.75 Mn |
| Feb 29, 2024 | 6.15 Mn |
| Nov 30, 2023 | 3.37 Mn |
| Aug 31, 2023 | 2.68 Mn |
| May 31, 2023 | 4.04 Mn |
| Feb 28, 2023 | 4.63 Mn |
| Nov 30, 2022 | 5.93 Mn |
| Aug 31, 2022 | 7.63 Mn |
| May 31, 2022 | 8.91 Mn |
| Feb 28, 2022 | 11.22 Mn |
| Nov 30, 2021 | 11.47 Mn |
| Aug 31, 2021 | 13.06 Mn |